TP53 mutation variant allele frequency is a potential predictor for clinical outcome of patients with lower-risk myelodysplastic syndromes
Open Access
- 6 May 2016
- journal article
- Published by Impact Journals, LLC in Oncotarget
- Vol. 7 (24) , 36266-36279
Abstract
TP53 mutation variant allele frequency is a potential predictor for clinical outcome of patients with lower-risk myelodysplastic syndromesKeywords
This publication has 27 references indexed in Scilit:
- Cutoff Finder: A Comprehensive and Straightforward Web Application Enabling Rapid Biomarker Cutoff OptimizationPLOS ONE, 2012
- Revised International Prognostic Scoring System for Myelodysplastic SyndromesBlood, 2012
- Incidence of 17p deletions and TP53 mutation in myelodysplastic syndrome and acute myeloid leukemia with 5q deletionGenes, Chromosomes and Cancer, 2012
- Clinical Effect of Point Mutations in Myelodysplastic SyndromesNew England Journal of Medicine, 2011
- Mutations in the p53 Tumor Suppressor Gene: Important Milestones at the Various Steps of TumorigenesisGenes & Cancer, 2011
- The lower risk MDS patient at risk of rapid progressionLeukemia Research, 2010
- Prognostic impact of age and gender in 897 untreated patients with primary myelodysplastic syndromesAnnals of Oncology, 2009
- Myelodysplastic syndromesBlood, 2008
- A prognostic score for patients with lower risk myelodysplastic syndromeLeukemia, 2007
- Prognostic Factors and Life Expectancy in Myelodysplastic Syndromes Classified According to WHO Criteria: A Basis for Clinical Decision MakingJournal of Clinical Oncology, 2005